Trial Parameters
Brief Summary
This research study involves the study of TriPRIL CAR T Cells for treating people with relapsed or refractory multiple myeloma and to understand the side effects when treated with TriPRIL CAR T Cells. This research study involves the study drugs:. * TriPRIL CAR T Cells * Fludarabine and Cyclophosphamide: Standardly used chemotherapy drugs as part of lymphodepleting process
Eligibility Criteria
Inclusion Criteria: * Ability to understand and the willingness to sign a written informed consent document. * Age ≥18 years at the time of signing informed consent. * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Life expectancy of greater than 12 weeks * Histologically or cytologically confirmed diagnosis of relapsed/refractory multiple myeloma. Documented measurable disease includes at least one or more of the following criteria: * Serum M-protein ≥1.0 g/dL * Urine M-protein ≥200 mg/24 hours * Involved serum free light chain ≥100 mg/L with abnormal κ/λ ratio * Bone marrow plasma cells ≥30% * Relapsed/refractory multiple myeloma with at least 3 prior regimens of systemic therapy including proteasome inhibitor, IMiDs and anti-CD38 antibody; or has "triple-refractory" disease following treatment with proteasome inhibitor, IMiD and anti-CD38 antibody, as part of the same or different regimens. Note: IMWG criteria defines refractory disease as disease progression on